Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05974696
Recruiting Observational

A Research Registry on Aggressive PitNETs

NCT05974696 · tracked via the Priya Life Science France tracker
Sponsor
Hospices Civils de Lyon
Phase
Observational
Started
2023-06-15
Last updated
2023-08-08

Condition(s) studied

Endocrine Tumor

Study summary

To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is unique in France and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. With more than 80 patient files discussed since its inception, the patient cohort via the HYPOcare RCP is one of the largest both nationally and internationally. At present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
* Inclusion Criteria : * Patients with a diagnosis of pituitary tumour * Patients whose file has been presented to the national HYPOcare RCP * Exclusion Criteria : * Patients objecting to participating in this research

Primary outcome measure(s)

  • Characterisation of aggressiveness of pituitary tumours by tanscriptome analysis — 3 years
    Molecular and transcriptomic signature of aggressiveness of pituitary tumours predictive of prognosis

Trial sites (1)

FacilityCityRegionStatus
Hospices Civils de Lyon - Groupement Hospitalier Est Lyon France Recruiting

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting
Validation of the French Version of the New Mobility Score (NMS) Recruiting
Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting
Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting
Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon

Other trials for the same condition

Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05974696 on ClinicalTrials.gov ↗ ← All trials in France